PDL/Roche Targeting Broad Zenapax Asthma Indication Under Development Deal

Roche signs on to PDL’s plans for daclizumab in development/marketing agreement for “asthma and related respiratory diseases.” PDL hopes initial asthma indication will be broader than that of Genentech/Novartis’ Xolair.